Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
As of today, Vertex Pharmaceuticals(VRTX) shares are valued at $444.25. The company's market cap stands at 112.85B, with a P/E ratio of 29.14.
As of 2026-04-02, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $438.00 and $446.15. The current price stands at $444.25, placing the stock +1.4% above today's low and -0.4% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 38.5K, compared to an average daily volume of 1.49M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $510.77 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $510.77 at its peak.
VRTX News
Vertex Pharmaceuticals received FDA approval to expand the use of ALYFTREK and TRIKAFTA to additional age groups and CFTR gene variants. The expanded labels ma...
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration, FDA, has approved expanded use of Alyftrek for the treatment of people with cysti...
Advertisement Is Vertex Pharmaceuticals stock offering a discount after recent weakness? Vertex Pharmaceuticals (VRTX) has seen its share price under pressure...
Analyst ratings
78%
of 36 ratingsMore VRTX News
Vertex Pharmaceuticals Inc. (VRTX) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter,...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Vertex Pharmaceuticals and keeping the price target at $600.00. Unlock hedge fund-level data...
Earlier in March 2026, analysts including Wells Fargo and Maxim updated their views on Vertex Pharmaceuticals, highlighting the company’s expanding pipeline in...
Key Points Multiple headwinds could bring the bull market to a halt. Stocks positioned to rise even during a market downturn include Berkshire Hathaway, Enbri...
Vertex Pharmaceuticals Inc. (VRTX) announced an update on their ongoing clinical study. Vertex Advances VX-407 Kidney Disease Program With Completed Early Stud...
Maze Therapeutics reported promising Phase II results for its APOL1-mediated kidney disease candidate MZE829. The company plans to move MZE829 into pivotal tes...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.